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Abstract
Background: The CXCL12/CXCR4 pathway regulates tumor cell proliferation, metastasis, angiogenesis and the
tumor-microenvironment cross-talk in several solid tumors, including glioblastoma (GBM), the most common and
fatal brain cancer. In the present study, we evaluated the effects of peptide R, a new specific CXCR4 antagonist that
we recently developed by a ligand-based approach, in an in vitro and in vivo model of GBM. The well-characterized
CXCR4 antagonist Plerixafor was also included in the study.
Methods: The effects of peptide R on CXCR4 expression, cell survival and migration were assessed on the human
glioblastoma cell line U87MG exposed to CXCL12, by immunofluorescence and western blotting, MTT assay, flow
cytometry and transwell chamber migration assay. Peptide R was then tested in vivo, by using U87MG intracranial
xenografts in CD1 nude mice. Peptide R was administered for 23 days since cell implantation and tumor volume
was assessed by magnetic resonance imaging (MRI) at 4.7 T. Glioma associated microglia/macrophage (GAMs)
polarization (anti-tumor M1 versus pro-tumor M2 phenotypes) and expressions of vascular endothelial growth
factor (VEGF) and CD31 were assessed by immunohistochemistry and immunofluorescence.
Results: We found that peptide R impairs the metabolic activity and cell proliferation of human U87MG cells and
stably reduces CXCR4 expression and cell migration in response to CXCL12 in vitro. In the orthotopic U87MG
model, peptide R reduced tumor cellularity, promoted M1 features of GAMs and astrogliosis, and hindered
intra-tumor vasculature.
Conclusions: Our findings suggest that targeting CXCR4 by peptide R might represent a novel therapeutic
approach against GBM, and contribute to the rationale to further explore in more complex pre-clinical settings
the therapeutic potential of peptide R, alone or in combination with standard therapies of GBM.
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Background
Glioblastoma (GBM), the most frequent and malignant
type of glioma, represents the most common and fatal
cancer of the central nervous system. Despite advances
in neurosurgery, chemotherapy and radiation therapy,
the median survival is approximately 15 months, due to
the recurrent and infiltrative nature of this tumor [1]. A
deep knowledge of GBM biology could lead to targeted
therapeutic approaches based on the inhibition of tumor
specific proteins or molecular pathways [2].
Gliomas are surrounded by resident non-tumor cells, in-
cluding infiltrating lymphocytes and a large number of
glioma-associated microglia/macrophages (GAMs), which
are correlated with the malignancy grade [3, 4] and can
support tumor structure, angiogenesis, growth and inva-
siveness in response to autocrine and paracrine molecular
regulators secreted by tumor cells [5, 6]. Metabolic cues
and molecular signals from glioma can instruct GAMs to
down-regulate the M1 pro-inflammatory potentially anti-
tumoral functions and to acquire a M2 anti-inflammatory,
immunosuppressive and pro-angiogenic phenotype, able
to foster neo-vascularization, matrix remodeling, tumor
growth, metastasis and recurrence, as well as to suppress
adaptive immunity, as reported for other solid tumors-
associated macrophages [7–10]. Although the molecular
signals implicated in macrophages-tumor cross talk re-
main largely unknown, chemokines and their cognate
receptors are receiving increasing attention [11–13]. In
particular, the chemokine receptor CXCR4, a G
protein-coupled receptor initially linked with leukocyte
trafficking and with HIV infection [14], is expressed in
various tumors including GBM, and high levels of ex-
pression have generally negative prognostic significance
[15–17]. The binding of its ligand, the chemokine stro-
mal cell-derived factor 1-α (SDF1-α, or CXCL12), trig-
gers different downstream signaling pathways in tumor
cells and in cells of the surrounding microenvironment,
which result in a variety of cellular responses including
angiogenesis, metastasis, proliferation and survival [18–
20]. It has been reported that high CXCL12 levels in
the tumor may attract CXCR4-positive vascular and in-
flammatory cells that, once within the tumor, secrete
tumor promoting cytokines as well as growth and pro-
angiogenic factors [21–24]. In the recent years, multiple
preclinical studies in animal models of glioma have
demonstrated that disrupting the CXCL12/CXCR4
pathway by specific antagonists affects tumor growth,
vasculogenesis and post-radiation recurrence, suggest-
ing that this approach represents a promising strategy
for glioblastoma therapy [25–28]. The CXCR4 antagon-
ist Plerixafor is the most studied and clinically ad-
vanced compound among the agents that inhibit
CXCL12/CXCR4 signaling [29]. It has been reported to
inhibit the growth of glioblastoma [25], and to limit the
survival of cancer stem cells derived from human glio-
blastoma [30]. However, Plerixafor lacks CXCR4 speci-
ficity because it also binds the other high-affinity
receptor for CXCL12, CXCR7, as an allosteric agonist
[31]. CXCR7 has been recently identified in several tu-
mors, including GBM in which it is involved in many
aspects of tumor biology [32, 33]. In addition, cardio-
toxicity and other adverse events were reported follow-
ing long-term usage of Plerixafor [34], prompting the
search for new safer and selective CXCR4 inhibitors
suitable as anti-GBM agents.
Recently, we have developed a new family of CXCR4
antagonists by a ligand-based approach [35]. Three of
these novel cyclic peptides impaired CXCR4 function in
vitro (competition with anti-CXCR4 antibody binding,
ligand dependent migration, calcium efflux and P-Erk
activation) and in vivo, reducing lung metastases in mice
injected with B16-CXCR4 mouse melanoma cells and
K7M2 mouse osteosarcoma cells. In the same study we
also demonstrated that these peptides do not affect
CXCR7 and CXCR3 binding [35].
In the present study, we evaluated, in a GBM model,
the potential effects of one of these novel cyclic peptides,
peptide R, which exhibited the best efficacy in inhibiting
CXCL12-dependent migration, ERK phosphorylation
and wound healing in human melanoma cells [35], and
strongly affected migration in osteosarcoma cells cul-
tured in presence of bone-marrow derived mesenchymal
stem cells [36]. The human glioblastoma U87MG cell
line was used for the evaluation of CXCR4 expression,
cell proliferation and migration in in vitro assays, as well
as for intracranial xenografts in nude mice for in vivo
studies. Peptide R effects were compared to those exerted
by Plerixafor. We demonstrate that peptide R generates an
unfavorable microenvironment for tumor cells by switch-
ing GAMs phenotype towards M1 features, and decreas-
ing intra-tumor vasculature. Our results are in support of
a therapeutic potential of peptide R in GBM treatment,
alone or in combination with standard therapies.
Methods
Glioma cell line and treatments
The human U87MG glioblastoma cell line from the
American Type Culture Collection (ATCC) was main-
tained in MEM (Life Technologies), supplemented with
10 % fetal bovine serum (FBS), 2 mM glutamine, 1 mM
sodium pyruvate, 100 μg/ml streptomycin and 100 U/ml
penicillin (all from Life Technologies).
After 24 hours of culture in complete medium, cells
were serum deprived for 16 h in MEM supplemented with
1 % of bovine serum albumin (BSA; Sigma-Aldrich).
Afterwards, medium was removed and replaced by fresh
medium; cells were stimulated or not with 100 ng/ml
CXCL12 (PeproTech) and cultured in absence or in
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presence of 10 μM Plerixafor (Sigma Aldrich) or with
10 μM of peptide R for 24, 48 and 72 h, on the basis of a
previous study [35].
Western blot analyses
U87MG cells were seeded at the density of 2.5 × 105/ml in
T-25 flasks, treated as described above and lysed in RIPA
buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1 % Non-
idet P-40, 0.5 % sodium deoxycholate, 0.1 % SDS), supple-
mented with protease and phosphatase inhibitor cocktails
(Hoffman-La Roche Ltd). Protein concentrations were
determined by Bradford’s protein assay (BioRad Labora-
tories) and 50 μg of total lysates were resolved by SDS-
PAGE (10 % polyacrylamide) under reducing conditions
and blotted with the polyclonal anti-human CXCR4 anti-
body (dilution 1:1000) and anti-β-actin monoclonal anti-
body (dilution 1:2000) (Sigma-Aldrich), followed by goat
anti-rabbit IgG (dilution 1:3000) and goat anti-mouse IgG
(dilution 1:3000) (BioRad Laboratories) HRP-conjugated
secondary antibodies.
Analysis of cell proliferation
U87MG cells were seeded in 6-well plates at the density
of 2 × 105/2 ml. After 24 h of culture in complete
medium cells were serum deprived, as described in the
previous section, and then the proliferation rate was
monitored by counting live and dead cells by Trypan
blue exclusion assay 24, 48 and 72 h after stimulation
with CXCL12 (100 ng/ml) and treatment with peptide R
or Plerixafor. Results represent three independent exper-
iments performed in triplicate.
MTT assay
U87MG cells were seeded in 96-well plates at the dens-
ity of 6 × 103 cells in 200 μl/well and treated with
CXCL12, Plerixafor or with peptide R, as described in
the previous “Treatments” section. MTT (5 μg/ml) was
added at each time point (24, 48, 72 h) during the final
2 h of treatment. After removing cell medium, 100 μl
DMSO were added and optical densities measured at
595 nm with a LT-4000MS Microplate Reader (Labtech
International Ltd). Measurements were made in tripli-
cates from three independent experiments.
Apoptosis and necrosis analysis
U87MG cells were seeded at the density of 2.5 × 105/ml in
T-25 flasks, treated as already described for 24, 48 and
72 h. Apoptosis was evaluated at each time point by meas-
uring phosphatidylserine externalization using Annexin
V-biotin (Bender MedSystems) followed by Alexa Fluor®
488-conjugated streptavidin (Life Technologies), and then
analyzed by FACSCalibur flow cytometer (BD Biosci-
ences). Necrosis was evaluated with the Propidium Iodide
(PI) supravital staining, as previously described [37].
Transwell chamber migration and invasion assays
Migration of U87MG cells was analyzed by a Transwell
chamber assay [38] using 8 μm-pore inserts (BD Biosci-
ences) which stood in 6-well plates (Corning). Cells were
seeded in serum free medium (1 × 106 cells/well) in the
Transwell chambers either with or without peptide R or
Plerixafor and allowed to migrate for 20 h at 37 °C. To
stimulate migration either FBS (10 %), as a positive control
of migration, or CXCL12, were added to the medium in
the well underneath the insert. Quantitative analysis and
SEM observations were performed as previously described
[39]. Six fields for each condition were examined.
Generation of human U87MG tumor xenografts and in
vivo treatments
CD1 nude mice (6 week-old) (Charles River) were anes-
thetized with intraperitoneal (i.p.) administration of keta-
mine hydrochloride (100 mg/kg) and xylazine (10 mg/kg),
then stereotactic injection of 25 × 103 U87MG cells, in
7 μl of PBS, was performed into the right caudate nucleus.
After glioma cell implantation, mice were randomly
assigned to control and to different treatment groups
(Plerixafor or peptide R) (n = 10 animals per group). The
experiment was repeated three times. Drugs were i.p.
injected at 1.25 mg/kg for Plerixafor [25] or at 2 mg/kg
for peptide R in sterile PBS [35], starting from the day of
cell injection, twice per day, for the entire treatment dur-
ation (23 days). Control mice received vehicle alone. In a
preliminary set of experiments we assessed the delivery of
the compound to the brain by using Peptide R conjugated
with a fluorescent tag (Tag-750) and optical imaging
(Xenogen IVIS system). The fluorescence was analyzed in
vivo and in the dissected brain (Additional file 1: Fig-
ure S1A, B, C). All animal procedures were approved
conforming to the Italian and European animal wel-
fare laws. Licence: Decreto Ministeriale n. 85/2012-B,
19-03-2012.
MRI imaging
Magnetic Resonance Imaging (MRI) experiments were per-
formed at 4.7 T, on Agilent-VARIAN INOVA SIS 200/183
system (Varian) equipped with a volume coil as transmitter
and a surface coil assembled with a stereotaxic mouse head
holder as receiver (RAPID Biomedical). Animals were
anesthetized with 1–2 % isofluorane in O2 (1 L/min)
(Forane, Abbott SpA), and body temperature was main-
tained constant by means of a water bed at 37 °C. MR
images were performed, post subcutaneous (s.c.) ad-
ministration of Gd-DTPA, with T1-weighted multi-slice
(TR/TE = 600/18 ms; NS = 4; slices thickness 0.6–1.0 mm).
Tumor volume was evaluated by using a dedicated image
browser program (Varian). Mice (n = 10 mice per group,
for each of the three independent experiments) were sub-
jected to MRI analysis at day 10, 15 and 23 days after cell
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implantation. An example of T1-weighted multi-slices is
given in Additional file 1: Figure S1D.
Immunofluorescence analysis and Immunohistochemistry
25 × 103 U87MG cells were seeded in 24-well cluster
plates onto 12-mm cover glasses. Cells were treated as
reported in “Glioma cell line and treatments” section.
To selectively detect the receptor expression cells were
stained, prior or post-fixation/permeabilization, with
the monoclonal anti-human CXCR4 antibody (dilution
1:100, R&D Systems), followed by goat anti-mouse
Alexa Fluor®488 (dilution 1:200, Life Technologies).
Coverslips were mounted with Vectashield® antifade
mounting medium containing DAPI (Vector Laborator-
ies). The observations were performed by confocal laser
scanning microscopy (CLSM) on a Leica TCS SP2 AOBS
apparatus, using excitation spectral laser lines at 405, 488,
543 and 594 nm. Image acquisition and processing were
conducted by using the Leica Confocal Software (Leica
Microsystems). Cells stained only with the fluorochrome-
conjugated secondary antibody were used to set up acqui-
sition parameters. Signals from different fluorescent
probes were taken in sequential scanning mode. Several
fields of view (>200 cells) were analyzed for each labeling
condition, and representative results are shown.
For the in vivo studies, 23 days after U87MG implant-
ation, animals were sacrificed and brains were processed
for immunofluorescence (IF), histochemistry and immu-
nohistochemistry (IHC) analyses. In particular, mice (n = 5
per group) were anesthetized and transcardially perfused
with PBS and then with 4 % PFA. Brains were removed
and post-fixed for 24 h at 4 °C. For IF, after fixation,
mouse brains were dehydrated overnight in PBS with 5
and 30 % sucrose. Serial 30 μm-thick coronal sections
were cut using a Reichert-Jung Frigocut cryostat and
stored at -20 °C in cryoprotective solution (PBS, 30 %
ethylene glycol and 30 % glycerol). IF staining was per-
formed on free-floating tumor-bearing sections, as previ-
ously described [40]. The following primary antibodies
were used in overnight incubations: rat anti-mouse
CD11b (1:100, Serotec), rabbit anti-human CD68 (1:200,
able to detect mouse, rat and human CD68, Santa Cruz),
mouse anti-mouse Arg-1 (1:200, BD Biosciences), rabbit
anti-mouse anti-iNOS (1:2000, Millipore), goat anti-
human vimentin (1:40, R&D Systems), rabbit anti-mouse/
human glial fibrillary acidic protein, GFAP (1:200, Dako),
rat anti-mouse CD31 (1:200, Serotec), mouse anti-human/
mouse vascular endothelial growth factor, VEGF (1:50,
R&D Systems). Sections were then incubated with
appropriate biotinylated (Vector Laboratories) or Cy3-
conjugated (Jackson ImmunoResearch) secondary anti-
bodies (1:200) for 2 h at room temperature, followed by
additional 2 h with Alexa Fluor® 488-conjugated streptavi-
din (1:200) and DAPI (300 nM in PBS; Sigma-Aldrich),
mounted with DABCO medium (Sigma-Aldrich). Images
were captured by a DFC420C camera on a Leica DM4000B
fluorescence microscope and by a Leica TCS SP2 confocal
microscope, as described above. CLSM images were ob-
tained by Z-projection of 25–30 optical sections taken from
the bottom to the edge of the tissue sections.
Quantification of fluorescence of CD68, CD11b and
iNOS immunoreactivity and colocalization analysis of
CD11b and iNOS immunoreactivity were performed using
ImageJ software (available at http://rsbweb.nih.gov/ij/),
and given as mean values ± SD of fluorescence intensity
and of % area of colocalization, respectively.
For histological and IHC analyses, mouse brains (n = 5
per group) were fixed in 4 % PFA coronal sections at 4
different levels were cut, in order to discover the exten-
sion of the tumor, then dehydrated, paraffin-embedded
and sectioned at 4 μm. For the histological analysis,
slides were stained with haematoxylin-eosin standard
method. For IHC sections were deparaffinized and rehy-
drated with standard procedures, incubated with 3 %
H2O2 (Sigma-Aldrich) for 15’ to block endogenous per-
oxidase activity, then incubated with normal goat serum
for 30’ and subsequently with mouse monoclonal anti-
vimentin (1:200) and rabbit polyclonal anti-GFAP (1:600).
For mouse primary antibody (vimentin) to minimize re-
activity of secondary anti-mouse antibody we used DAKO
ARK™ (Animal Research Kit), based on avidin-biotin and
Peroxidase method. For GFAP staining, sections were in-
cubated with anti-rabbit Envision® peroxidase conjugated
as secondary antibody, for 1 h at room temperature. All
antibodies were from Dako. Finally, slides were reacted with
diaminobenzidine (DAB Substrate Chromogen System,
Dako), counterstained with haematoxylin and mounted, ob-
servations were performed on randomly selected samples
per group, and all brain sections obtained with these proce-
dures were analyzed.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 3.03 Software (GraphPad Software Inc.). All data
were compared by two-tailed unpaired Student t-Test or
one-way ANOVA. Differences were considered signifi-
cant when P < 0.05.
Results
CXCR4 expression in U87MG cells
Confocal laser scanning microscopy analyses were per-
formed on U87MG cells in order to evaluate CXCR4
expression in response to the different treatments. Cells
were first serum deprived (16 h) and stimulated or not
with CXCL12 (100 ng/ml). CXCL12-stimulated cells
were then cultured in absence or in presence of peptide
R (10 μM) or Plerixafor (10 μM) for 24, 48 and 72 h. At
each time point, one group of U87MG cultures was
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Fig. 1 CXCR4 expression in U87MG cell line. a CLSM analyses of U87MG cells stimulated (+) or not (-) with CXCL12 (100 ng/ml) and treated (+)
with peptide R (10 μM) or Plerixafor (10 μM) or left untreated (−). After 48 or 72 h of culture cells were stained with anti-CXCR4 mAb (green) prior
to (UNFIXED, top panel) or after (FIXED, bottom panel) fixation with 3 % PFA. Nuclei were stained with DAPI (shown in blue). Scale bars, 15 μm.
b Representative western blot analysis of CXCR4 detection in U87MG cells processed after 24, 48 and 72 h of treatments as described in
(a). β-actin was used as loading control. Histograms represent the relative fold change of CXCR4 expression normalized to β-actin, obtained with
densitometric analyses of western blot bands (Image J software). Means ± SD of n = 3 independent experiments. Statistical analyses were performed
with one-way ANOVA, * P = 0.0042
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stained for CXCR4 detection on cell membrane surface,
another one was fixed and permeabilized before staining
to assess CXCR4 intracellular expression. No effects on
membrane CXCR4 expression were observed after 24 h of
treatments (data not shown). At 48 h (Fig. 1a, top panel,
Unfixed), CXCL12 stimulation increased CXCR4 mem-
brane expression as compared to unstimulated cells
(-CXCL12). The receptor completely disappeared from
the cell surface of U87MG cells after peptide R or Plerixa-
for treatment. After 72 h, CXCR4 down-modulation on
cell membrane of peptide R-treated cells was maintained,
while in Plerixafor-treated cells the chemokine receptor
was re-expressed at levels comparable to unstimulated
(-CXCL12) or CXCL12-stimulated cells (+CXCL12). As
reported in Fig. 1a (bottom panel, Fixed), after 48 h
CXCR4 was still exposed on the membrane upon stimula-
tion with CXCL12 alone; the receptor was instead inter-
nalized after treatment with either peptide R or Plerixafor,
with the lowest levels of expression detected in the
presence of peptide R. At the following time point (72 h),
in Plerixafor-treated cells CXCR4 expression and distribu-
tion were restored as in control cultures (+CXCL12),
while in peptide R-treated cells the reduction of CXCR4
expression was maintained. Densitometric analysis of
western blotting experiments showed a significant de-
crease of CXCR4 total content in U87MG cells exposed
to peptide R for 48 h (45 % compared to unstimulated
cells and 33 % compared to CXCL12-stimulated cells)
and confirmed a downregulation of the receptor after
72 h compared to the other experimental conditions
(Fig. 1b).
Effects of peptide R on U87MG cell growth, viability and
migration
To investigate the possible functional effects induced by
CXCR4 down-modulation, we evaluated cell proliferation
after exposure of U87MG cells to peptide R or Plerixafor
in the same conditions of the previous experiments. Cells
Fig. 2 Effects of peptide R on cell proliferation, vitality and migration. a Cell counting of U87MG cells stimulated (+CXCL12) or not (-CXCL12)
with 100 ng/ml of CXCL12 and treated with Plerixafor (10 μM) or peptide R (10 μM) for 24, 48 and 72 h. Mean values ± SD of n = 3 independent
experiments. **** P = 0.0001, one-way ANOVA, (asterisks represented in the figure). P = 0.0293 (–CXCL12 cells versus peptide R-treated cells), P = 0.0005
(+CXCL12 cells versus peptide-treated U87MG) (72 h of treatments), unpaired two-tailed Student t-test. b MTT assay performed on U87MG cells after
72 h incubation with CXCL12, in the presence of peptide R or Plerixafor, compared to untreated cells (-CXCL12) (means ± SD of n = 3
independent experiments). **** P = 0.0001 (asterisks represented in the figure), one-way ANOVA. P = 0.0148 (-CXCL12 cells versus Plerixafor-treated
U87MG), P = 0.0419 (-CXCL12 versus peptide R-exposed cells), P = 0.0084 (+CXCL12 cells versus peptide R-treated U87MG cells), unpaired two-tailed
Student t-test. c Quantitative analysis of U87MG cells migration (for details see Methods section) in response to 10 % FBS (black bar) or in response to
CXCL12 in the absence or presence of peptide R or Plerixafor. The percentages of area occupied by migrating cells are reported as mean values ± SD
(n = 6). **P = 0.0024 (asterisks shown in the figure) one-way ANOVA. P = 0.0425 (+CXCL12 versus + Plerixafor), P = 0.0029 (+CXCL12 versus+ peptide R
cells), unpaired two-tailed Student t-test. d Scanning electron microscopy (SEM) observations were performed at the end of the 20-hour
assays on cells treated as described in (c). Imaging was performed on both the upper (panels a–c) and lower sides (panels d–f) of the
filter. Asterisks represent the migration leader elements. Scale bars are indicated
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were seeded 24 h before adding the different drugs and
cell proliferation rate was determined 24, 48, and 72 h
after treatments (Fig. 2a). Consistently with an endogen-
ous production of CXCL12 by U87MG cells [41], we ob-
served an increase in cell number over the 72 h of
observation in the absence of added chemokine (Fig. 2a,
black bars). Minimal or no changes in cell proliferation
were observed at 24 and 48 h of cell culture. At 72 h
CXCL12 moderately increased the cell number; after pep-
tide R treatment a 35 % reduction of cell proliferation was
observed compared to CXCL12-stimulated cells, and a
20 % reduction compared to unstimulated (-CXCL12)
cells. Plerixafor-treated cells showed a moderate reduction
in cell proliferation compared to CXCL12-stimulated cells,
which did not reach statistical significance.
Evaluation of Annexin V-positive or PI-bright cells at
the same time points showed that neither peptide R nor
Plerixafor exerted any appreciable apoptotic or necrotic
effect (data not shown). Next, cell viability was assessed
by MTT assay. No significant effects were induced by
both treatments at 24 and 48 h (data not shown); how-
ever, a significant reduction in the metabolic activity of
U87MG cells was observed in both peptide R- and
Plerixafor-treated cells (Fig. 2b).
Since we previously showed that peptide R inhibits cell
motility of melanoma and osteosarcoma cells [35, 36],
Fig. 3 In vivo effects of peptide R treatment of U87MG orthotopic mouse model. a Tumor volume measures obtained by MRI analyses performed on
mice at day 10, 15 and 23 after U87MG cells implantation and drug administration. Curves represent mean value of tumor volumes measures of three
independent experiments obtained from mice treated with vehicle (PBS) ● CTRL, ■ Plerixafor and ▲ peptide R (n = 10 animals per group,
error bars ± SD). b Representative brain sections of vehicle-treated (CTRL) or peptide R- or Plerixafor-treated mice stained by immunohistochemistry
with the anti-vimentin antibody. Scale bars, 75 μM. c Representative CLSM images of Vimentin expression (green) of tumor-free contralateral
hemispheres of vehicle-treated mice (CTRL), peptide R- and Plerixafor-treated mice. Arrows represent Vimentin + cells. Nuclei were stained with
DAPI (blue). Scale bars 75 μM
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we tested the effects exerted by peptide R and by Plerix-
afor, on glioma cells migration. U87MG cells, in serum
free medium, were seeded in transwell chambers and
allowed to migrate towards the chemokine CXCL12
(added to the lower chamber medium) in the absence or
presence of peptide R. In addition to CXCL12, FBS was
also used as positive control for migration (black bar in
Fig. 2c). Quantitative analysis by computer-assisted light
microscopy (Fig. 2c), showed that, as expected, CXCL12
stimulated U87MG cell migration, Plerixafor treatment
did not induce significant changes, while peptide R sig-
nificantly reduced the percentage of area occupied by
migrating cells. Scanning electron microscopy (SEM)
analysis of the upper side of the filter showed that dur-
ing migration U87MG cells exposed to FBS or CXCL12
move as chains or group of cells (Fig. 2da,b). The pres-
ence of peptide R hampered cell migration through the
membrane pores, and U87MG cells appeared organized
in tight clusters (Fig. 2dc). On the lower side of the filter
numerous cells were visible in control (FBS) or
CXCL12-treated cells (Fig. 2dd,e), while in the presence
of peptide R very few cells crossing membrane pores
were recorded (Fig. 2df ).
In vivo effects of peptide R in the orthotopic U87MG
mouse model
The above in vitro results supported the potential anti-
tumor effects of peptide R on glioma cells. To test this
hypothesis in vivo, we used intracranial orthotopic xeno-
grafts of U87MG cells. Tumor volume and localization
were evaluated by MRI analyses in mice treated with ve-
hicle, peptide R or Plerixafor, as reported in Methods.
Volumetric analysis (Fig. 3a) performed at day 10, 15
and 23 after U87MG cells implantation and treatments
did not show any significant change of tumor size in ani-
mals treated with both CXCR4 antagonists, compared to
Fig. 4 Peptide R effect on macrophages/microglial cells accumulation in U87MG glioma. a Representative CLSM analyses of brain sections of
vehicle-treated (CTRL), peptide R- or Plerixafor-treated mice stained with anti-CD11b (red) and CD68 (green, a marker for activated microglia)
antibodies. Arrows indicate the tumor edge, while asterisks (*) indicate the tumor-free parenchyma. Scale bars, 30 μm. b Mean intensity of
CD11b and CD68 fluorescence were analysed by Image J software and reported as mean values ± SD (n = 4–5 images for each treatment
group). *P = 0.0420 and **P = 0.0066 (asterisks shown in figure), one-way ANOVA. P = 0.0476 and P = 0.0056 (peptide R versus CTRL), unpaired
two-tailed Student t-test
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control group (PBS-treated mice, CTRL). However, immu-
nohistochemical analyses of brain slices showed a reduc-
tion of U87MG cells, as identified by vimentin expression,
after treatment with peptide R when compared to Plerixa-
for or PBS treatment (Fig. 3b), thus suggesting a reduced
tumor cell density in peptide R-treated mice. Interestingly,
in the contralateral hemisphere no vimentin+ cells were
detected either after peptide R or Plerixafor treatment
(Fig. 3c), suggesting that both CXCR4 antagonists could
abrogate dissemination of glioblastoma cells at distant
cerebral sites.
To better analyze the in vivo effects of peptide R, we ex-
amined the possible involvement of glioma microenviron-
ment in controlling tumor growth and dissemination. By
Fig. 5 In vivo effects of peptide R treatment on iNOS expression by macrophage/microglia. a CLSM analyses of the double staining with CD11b
(red) and iNOS (green) antibodies performed on brain sections of vehicle-treated (CTRL), or peptide R- or Plerixafor-treated mice. Images were
taken both in the tumor core and at the tumor edge, as indicated. Asterisks (*) indicate the tumor-free parenchyma. Scale bars, 50 μm. b Mean
intensity of CD11b and iNOS fluorescence (upper panels) and percentage of colocalized area (lower panel) in the tumor core were analysed by
Image J software and reported as mean values ± SD (n = 4 images for each treatment group). *P = 0.0226 and **P = 0.0057 (asterisks shown in
figure), one-way ANOVA. P = 0.0448 and P = 0.0084 (peptide R versus CTRL and Plerixafor), unpaired two-tailed Student t-test
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immunofluorescence analysis we investigated the expres-
sion of typical markers of GAMs, such as CD11b (cluster
of differentiation molecule 11b) and CD68 (a lysosomal
glycoprotein used as a marker for activated microglia/
macrophages). As shown in Fig. 4, peptide R-treated gli-
omas showed a reduction of CD11b+ and CD68+ cells mi-
grated at the tumor edge (Fig. 4a and b) as compared
with control and Plerixafor groups. Moreover, in the
untreated and Plerixafor-treated tumors we detected
more CD11b+/CD68+ cells respect to peptide R-treated
gliomas, suggesting that peptide R treatment perturbs
the activation state of GAMs. It is worth noting that
glioma cells express the CD68 marker, as confirmed by
immunostaining of U87MG cells in vitro (Additional
file 2: Figure S2A) and as previously reported [42].
Since the antibody used in the present study recognizes
CD68 of mouse and human origin, the observed reduc-
tion of CD68 expression could be related not only to
GAMs but also to a reduced number of U87MG cells,
consistently with the observed decrease in vimentin+
cell density (Fig. 3b).
As a marker of astrocyte reactivity, we performed GFAP
(glial fibrillary acidic protein) staining by both immuno-
fluorescence and immunohistochemistry. Both techniques
evidenced a stronger reactivity in peptide R-treated tu-
mors (Additional file 2: Figure S2B). Since U87MG cells
do not express GFAP, the observed staining can be solely
associated with astrocytes [43].
In vivo effects of peptide R on GAM reactivity
In order to better understand the functional relevance of
CD11b+ cells infiltrating glioma and the influence of
CXCR4 inhibition on the functional phenotype of these
cells, we analyzed the expression of inducible nitric oxide
synthase (iNOS), an enzyme typically involved in microglia/
macrophage pro-inflammatory activity (M1 phenotype),
and arginase-1 (Arg-1), as a marker of immunosuppressive
activity (M2 phenotype).
Observations performed by double immunofluores-
cence staining of CD11b and iNOS revealed a strong
expression of iNOS by CD11b+ cells within the tumors
of peptide R-treated mice, compared to control and
Plerixafor-treated mice (Fig. 5a and b, Tumor core), sug-
gesting that peptide R treatment promotes M1 proper-
ties in GAMs. Analyses of the tumor margin indicated
the presence of CD11b-/iNOS+ cells in the peritumoral
area of control gliomas only (Fig. 5a, Tumor edge, indi-
cated by a star). No differences were detected in Arg-1
expression by CD11b+ cells among treated and control
mice (Fig. 6). However, we detected a higher number of
iNOS+/Arg-1+ in peptide R-treated gliomas (Fig. 7),
Fig. 6 In vivo effects of peptide R treatment on Arg-1 expression by glioma-associated macrophage/microglia. Detection of CD11b- (red) and
Arg-1- (green) positive cells in brain sections of mice treated with peptide R or Plerixafor or left vehicle-treated (CTRL). Scale bars, 75 μm. On the
right of each panel a magnification is reported, scale bars 30 μm
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further supporting the ability of the novel CXCR4 antag-
onist to modulate the reactivity of GAMs.
Interestingly, untreated and Plerixafor-treated gliomas
presented Arg-1+ endothelial-like tubular structures in the
tumor core. Such structures were absent in peptide R-
treated tumors (Fig. 6, higher magnifications on the right).
The effect of peptide R on tumor vasculature was
further investigated by double staining for endothelial
related markers, such as CD31 and VEGF. We observed
a strong reduction of CD31+/VEGF+ and CD31-/VEGF+
cells in the tumor core of mice treated with peptide R,
in comparison with control and Plerixafor-treated mice
(Fig. 8). In the tumor-free parenchyma, we observed a
low expression of VEGF and CD31, without any signifi-
cant differences among the different treatments (Fig. 8,
Contralateral hemisphere).
Discussion
There is an urgent need in identifying novel therapeutics
that will improve survival in GBM patients. The CXCL12-
dependent signalling has emerged among the most
relevant molecular pathways that can be targeted to suc-
cessfully interfere with tumor cell proliferation, survival,
migration, and radioresistance [18].
Here we show the efficacy of the newly synthesized
CXCR4 antagonist peptide R in modulating the intrinsic
properties of glioblastoma cells and their microenviron-
ment in an experimental model of GBM. We found that
peptide R stably reduced the expression of CXCR4 in
human U87MG cells and impaired their metabolic activ-
ity, cell proliferation and migration in response to
CXCL12 in vitro. Accordingly, in the orthotopic U87MG
mouse model, peptide R reduced tumor cellularity, abro-
gated dissemination of glioblastoma cells at distant cere-
bral sites, promoted M1 features in GAMs recruited to
the tumor area and impaired intra-tumor vasculature.
In our model, peptide R effects were comparable to
those observed with Plerixafor, the best-characterized and
most widely used antagonist of CXCR4. The two drugs
share a common core of ligand-receptor interactions, but
they span different subsites possibly explaining differences
in specific activities of the two drugs. Indeed, peptide R,
unlike Plerixafor, is devoid of agonism to CXCR7, and this
property could represent an advantage in the inhibition of
CXCL12-dependent signaling [35]. Recent works indicate
that glioma and tumor-associated vasculature can express
CXCR7, and its expression increases with glioma grade
[32]. It is noteworthy that rodent microglia co-express
CXCR4 and CXCR7 as a functional receptor unit, which
is essential for controlling CXCL12-dependent migration
and proliferation, and which is up regulated by classical
M1 activators [44].
Fig. 7 Effects of peptide R on the co-expression of iNOS and Arg-1 enzymes in glioma associated macrophages/microglial cells. Immunofluorescence
analyses of iNOS (red) and Arg-1 (green) performed on brain slices of vehicle-treated (CTRL), peptide R- or Plerixafor-treated mice. The insert in the
peptide R-treated sample is a magnification of the area indicated by the arrows. Scale bars, 50 μm
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The entire axis CXCR4–CXCL12–CXCR7 regulates
the mammalian target of rapamycin (mTOR) signaling
in renal cancer cells, a pathway identified in several hu-
man malignancies and effectively blocked by peptide R
in these cells [45]. These findings have important impli-
cations also for brain tumors, as mTOR is a crucial
modulator of inflammatory pathways in microglia and
macrophages. Lisi and colleagues [46] reported that mTOR
kinase inhibitors polarize glioma-activated microglia to the
M1 phenotype. Although the links among the various
functions of macrophages, tumor progression and therapy
responses are still poorly defined, the M1/M2 balance has
emerged as a crucial factor able to control glioma biology
and radioresitance [47, 48]. Interestingly, peptide R treat-
ment in the GBM model induced a strong GAM immuno-
reactivity for the M1 marker iNOS, potentially increasing
the anti-tumor killing functions of these macrophages [49].
Although the expression of the M2 marker Arg-1 was not
modified in GAMs, the enhanced expression of iNOS
indicates that peptide R interferes with the phenotype
switching of GAMs towards M2 pro-tumorigenic functions
induced by the cross-talk with tumor cells.
Recent results of genome-wide analyses have shown
that GAMs represent a unique population, expressing a
mixture of M1 and M2-specific genes, although the cel-
lular heterogeneity of GAMs was not investigated [9]. In
our model, the co-expression of the two markers (iNOS
and Arg-1) in most GAMs of peptide R-treated tumors
supports the existence of a mixed phenotype and sug-
gests that peptide R treatment might slow down the
polarization to a more homogeneous M2 population.
While peptide R treatment induced iNOS expression in
Fig. 8 In vivo effects of peptide R on U87MG glioma vascularization. CLSM analyses on brain sections of untreated (CTRL) or peptide R- or
Plerixafor-treated mice for the detection of CD31 (endothelial marker, red) and VEGF (angiogenic factor, green). Images were taken both in the
tumor core and in the contralateral hemisphere. Scale bars, 75 μm
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GAMs (CD11b positive cells), it conversely reduced iNOS
in CD11b negative cells at the tumor margins. The func-
tional significance of this differential regulation of iNOS
in different cell populations by peptide R could reflect the
complexity of nitric oxide (NO) effects on tumor biology,
which appears dependent on NO levels and cellular
sources. Low concentrations of NO have been positively
associated with tumor growth, migration, invasion, sur-
vival, angiogenesis, and metastasis while high NO levels
by dendritic/macrophage cells elicit tumoricidal activity
[50, 51]. Down-regulation of iNOS in non-macrophage
cells at the tumor edges and up-regulation in GAMs in
the tumor core could represent a dual protective mechan-
ism of peptide R against tumor growth and dissemination.
In addition, peptide R reduced the presence of CD31/
VEGF positive cells and Arg-1-expressing vessel-like struc-
tures in the tumor core, suggesting that a reduced ab-
errant intratumoral vascularization could represent a
further important anti-tumoral mechanism of peptide
R. Anti-angiogenic therapies in GBM patients indicate
the promising benefits of these approaches [52]. This
peptide R effect is in line with the recognized role of
CXCL12 in angiogenesis and vasculogenesis, but it
could also arise by the modulation of GAM reactivity
and the retention of M1 functions, less prone to the
enhancement of angiogenesis [53–55].
Overall, our data suggest that the potential of peptide
R as anti-cancer agent, shown by previous in vivo
models of lung metastases (B16-CXCR4 and KTM2
murine osteosarcoma cells) and primary growth of hu-
man renal cell xenografts [35] can be exploited also in
anti-GBM therapy. Peptide R could enhance the efficacy
of standard treatments such as radiation, chemo- and
anti-VEGF therapies, known to up-regulate CXCL12 and
CXCR4 as part of the escape program that favors tumor
recurrence and dissemination at distance, restores the
vasculature and promotes GAM recruitment [56, 57].
The recruitment of circulating cells outside of the radi-
ation field that can recolonize and/or stabilize the tumor
vasculature after irradiation has been suggested as a
mechanism of GBM resistance to irradiation. Consist-
ently, post-radiation therapy inhibition of CXCL12/
CXCR4 interaction resulted in the inhibition of tumor
recurrence in glioma models [24, 28].
Conclusions
In our GBM mouse model, Peptide R appears to modulate
not only tumor cell intrinsic properties but also those of
GAMs and their microenvironment, thus engaging a feed
forward loop able to counteract glioblastoma growth and
dissemination. These encouraging experimental results, to-
gether with data showing no overt toxicity of peptide R in
mice [35], contribute to the rationale to further explore the
therapeutic potential of peptide R, alone or in combination
with standard therapies in more complex pre-clinical GBM
models.
Additional files
Additional file 1: Figure S1. In vivo and ex vivo imaging. In vivo
fluorescence images obtained using an IVIS Spectrum bioluminescent
and fluorescent imaging system from Xenogen (IVIS Lumina II). Excitation
and emission values (640 nm, 700 nm, respectively) were kept constant,
and exposure times 7 s were used. A) Example of tumor-bearing mouse
at 21th of growth, fluorescence imaging observed at 1 h 30’ after of peptide
R (conjugates to VIVOTAG-S 750 fluorochrome) i.v. injected. The animal was
placed dorsally under anaesthesia in a light-tight chamber. After final in vivo
fluorescence imaging, the animals were euthanized, and the brain of
animals were carefully excised, the intensity of fluorescence was in-
creased in brain with tumor (B) respect to the healthy brain (C). Light
emitted from the animal/brain appears in pseudocolor scaling.
D) Representative multi-slice coronal postcontrast-enhanced (Gd) T1-
weighted MR images (4.7 T) of tumor-bearing mouse brain Contrast
enhanced-MRI evidences that tumor lesion has almost uniformly disrupted
BBB. (TIF 4589 kb)
Additional file 2: Figure S2. A) CD68 expression on U87MG cell line.
Representative CLSM analysis of CD68 expression (green) on U87MG cells.
Nuclei were stained with DAPI (blue). Scale bars, 47 μM. B) In vivo effect
of peptide R on astrocytes reactivity. GFAP (marker of astrocyte reactivity)
detection by CLSM (on the left) and immunohistochemistry (on the right)
on brain sections of mice treated with peptide R or left untreated
(CTRL). Asterisks (*) indicate the tumor-free parenchyma. Scale bars,
30 μM. (TIF 1451 kb)
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